Theseus Pharmaceuticals, Inc. (THRX) News & Overview - Discounting Cash Flows
THRX
Theseus Pharmaceuticals, Inc.
THRX (NASDAQ)

THRX's Business Model

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Sector & Industry Healthcare / Biotechnology
Website https://theseusrx.com
CEO (Chief Executive Officer) Iain D. Dukes DPHIL,
Number of Employees
IPO date October 7, 2021

THRX Latest News

Contact
CountryUS
Address245 Main Street
CityCambridge
StateMA
Phone857 400 9491
Zip Code02142
Other Identifiers
CIK0001745020
ISINUS88369M1018
CUSIP88369M101
Open4.06
Previous Close4.06
Volume677.7 Thou.
Average Volume849.6 Thou.
Day’s Range4.06 – 4.07
52 Week Range2.05-12.37
MA (50)3.9506
MA (200)4.99585
Market Cap181.5 Mil.
Shares Out.44.65 Mil.
Earnings DateMar 09, 2024
Beta
Last Dividend
EPS
PE

Industry Competitors for THRX

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us